Loading...

Catalent, Inc.

CTLTNYSE
Healthcare
Drug Manufacturers - Specialty & Generic
$63.48
$0.00(0.00%)

Catalent, Inc. (CTLT) Stock Overview

Explore Catalent, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 67.3/100

Key Financials

Market Cap11.5B
P/E Ratio-27.97
EPS (TTM)$-2.28
ROE-0.11%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$60.70

CTLT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Catalent, Inc. (CTLT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $60.70.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -27.97 and a market capitalization of 11.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
2.46%
2.46%
Profit Growth
$-2.27
349.57%
EPS Growth
$-2.27
350.00%
Operating Margin
1.27%
446.72%
ROE
-11.44%
349.57%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0

Price Targets

Low$63.50
Average$63.50
High$63.50

Company Profile

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CEO

Alessandro Maselli

Employees

17,000

Headquarters

14 Schoolhouse Road, Somerset, NJ

Founded

2014

Frequently Asked Questions

;